Dynamic Mutations, Non-Coding RNAs and RNA-Mediated Disease
The human genome contains a complex array of repetitive DNA sequence elements including transposon-derived/interspersed repeats, segmental duplications, large tandemly repeated sequences and simple sequence repeats (microsatellites). Microsatellite instability is associated with nearly 30 hereditary disorders. Disease may result from repeat expansions within a coding region and synthesis of a toxic protein (e.g., Huntington’s disease). Alternatively, many microsatellites are located in non-coding regions and cause diseases such as spinocerebellar ataxia types 8, 10 and 12 (SCA8, SCA10, SCA12), fragile X-associated tremor ataxia syndrome (FXTAS) and several types of myotonic dystrophy (CDM, DM1, DM2). How do simple repeat expansions in non-coding regions result in disease? To answer this question, we have focused on myotonic dystrophy because it is a dominantly-inherited disorder associated with non-coding CTG and CCTG expansion mutations in two different genes, DMPK (DM1) and ZNF9 (DM2), which lead to similar disease phenotypes. We proposed the RNA-mediated disease model in which mutant DM1 and DM2 mRNAs are trapped in the nucleus and sequester (C)CUG repeat binding proteins that are essential for normal tissue development and maintenance. Our lab identified these sequestered factors as the muscleblind-like (MBNL) proteins. Ongoing efforts are focused on elucidating the normal functions of these proteins as well as investigating whether RNA toxicity has a pathogenic role in other hereditary disorders.
Regulation of RNA Processing During Development
During embryogenesis and postnatal development, mammalian tissues are initially formed and subsequently remodeled to meet the evolving demands of the developing organism. This process requires a dynamic series of biochemical events at both the transcriptional and post-transcriptional levels. While considerable effort has been spent on clarifying DNA sequence elements and trans-acting factors involved in transcriptional regulation, less is known about the post-transcriptional steps required for normal tissue genesis and maturation. Many genes encode multiple protein isoforms that are generated by alterative splicing of pre-mRNAs and we are interested in understanding the mechanistic basis for these splicing transitions during skeletal muscle and brain development. Recent studies have focused on the roles of two alternative splicing factors, MBNL1 and CUGBP1, in regulating alternative exon splicing during the neonatal to adult transition. We are currently investigating additional factors and pathways that impact RNA processing during development and how disruption of these pathways results in disease.
Neurodegeneration in Myotonic Dystrophy
The human brain contains ~1011 neurons which are interconnected through a vast network of synapses. This highly interactive cell system requires an extraordinary level of protein diversity, much of which is generated by alternative processing of gene transcripts. The brain is severely affected by the multi-systemic disorder myotonic dystrophy (DM). These CNS effects can be subdivided into developmental (DM type 1 disease only) and degenerative changes (DM1 and DM2). This distinction between DM1 and DM2 in the CNS is strikingly similar to disease-associated effects observed in muscle where developmental abnormalities (e.g., hypotonia, respiratory insufficiency) are only observed in DM1 (congenital DM1 or CDM) while adult-onset degenerative changes (muscle weakness/wasting) occur in both DM1 and DM2. Our long term goal is to test the hypothesis that DM-associated CNS deficits result from disruption of the normal steps in the expression and pre-mRNA processing of specific gene transcripts and to clarify how the corresponding biochemical pathways are adversely affected in the DM brain.
Postdoctoral Fellow, Northwestern University
Ph.D., University of California, Berkeley
B.A., Colorado College
Faculty Achievement Recognition, University of Florida
Research Foundation Professor, University of Florida
Established Investigator, American Heart Association
Junior Faculty Research Award, American Cancer Society
National Science Foundation Postdoctoral Fellow
Chaim Weizmann Postdoctoral Fellow
Chancellor’s Patent Fund Award, University of California, Berkeley
BCH 6415 Advanced Molecular and Cellular Biology
BCH 7410 Advanced Gene Regulation
GMS 6001 Fundamentals of Biomedical Sciences
GMS 6905 Independent Studies in Medical Sciences (BMS Laboratory Rotations)
GMS 6971 Master’s Research
GMS 7191 Research Conference
GMS 7980 Doctoral Research